Cargando…
Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases
Neurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both com...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503806/ https://www.ncbi.nlm.nih.gov/pubmed/36144268 http://dx.doi.org/10.3390/metabo12090864 |
_version_ | 1784796057189744640 |
---|---|
author | Lanznaster, Débora Dingeo, Giulia Samey, Rayhanatou Altine Emond, Patrick Blasco, Hélène |
author_facet | Lanznaster, Débora Dingeo, Giulia Samey, Rayhanatou Altine Emond, Patrick Blasco, Hélène |
author_sort | Lanznaster, Débora |
collection | PubMed |
description | Neurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both common and specific alterations regarding metabolite levels. In this review, we were interested in identifying metabolite alterations that have been reported in preclinical models of NDs and that have also been documented as altered in NDs patients. Such alterations could represent interesting targets for the development of targeted therapy. Importantly, the translation of such findings from preclinical to clinical studies is primordial for the study of possible therapeutic agents. We found that N-acetyl-aspartate (NAA), myo-inositol, and glutamate are commonly altered in the three NDs investigated here. We also found other metabolites commonly altered in both AD and PD. In this review, we discuss the studies reporting such alterations and the possible pathological mechanism underlying them. Finally, we discuss clinical trials that have attempted to develop treatments targeting such alterations. We conclude that the treatment combination of both common and differential alterations would increase the chances of patients having access to efficient treatments for each ND. |
format | Online Article Text |
id | pubmed-9503806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95038062022-09-24 Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases Lanznaster, Débora Dingeo, Giulia Samey, Rayhanatou Altine Emond, Patrick Blasco, Hélène Metabolites Review Neurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both common and specific alterations regarding metabolite levels. In this review, we were interested in identifying metabolite alterations that have been reported in preclinical models of NDs and that have also been documented as altered in NDs patients. Such alterations could represent interesting targets for the development of targeted therapy. Importantly, the translation of such findings from preclinical to clinical studies is primordial for the study of possible therapeutic agents. We found that N-acetyl-aspartate (NAA), myo-inositol, and glutamate are commonly altered in the three NDs investigated here. We also found other metabolites commonly altered in both AD and PD. In this review, we discuss the studies reporting such alterations and the possible pathological mechanism underlying them. Finally, we discuss clinical trials that have attempted to develop treatments targeting such alterations. We conclude that the treatment combination of both common and differential alterations would increase the chances of patients having access to efficient treatments for each ND. MDPI 2022-09-14 /pmc/articles/PMC9503806/ /pubmed/36144268 http://dx.doi.org/10.3390/metabo12090864 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lanznaster, Débora Dingeo, Giulia Samey, Rayhanatou Altine Emond, Patrick Blasco, Hélène Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title_full | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title_fullStr | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title_full_unstemmed | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title_short | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
title_sort | metabolomics as a crucial tool to develop new therapeutic strategies for neurodegenerative diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503806/ https://www.ncbi.nlm.nih.gov/pubmed/36144268 http://dx.doi.org/10.3390/metabo12090864 |
work_keys_str_mv | AT lanznasterdebora metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT dingeogiulia metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT sameyrayhanatoualtine metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT emondpatrick metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT blascohelene metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases |